Savya Agarwal

Optimizing iPSC Stability and Reprogramming: Bridging Regenerative Medicine and Cancer Treatment through ATFCs

Started Aug. 22, 2024

Abstract or project description

Induced Pluripotent Stem Cells (iPSCs) have great potential in regenerative medicine for patient-specific treatment of neurodegenerative, cardiovascular, and metabolic diseases. Low reprogramming efficiency, genetic instability, immunogenicity, and scalability, however, are major setbacks for clinical translations. Emerging CRISPR-mediated gene editing, epigenetic regulation, and AI-driven quality control are anticipated to enhance the stability, safety, and reproducibility of iPSCs. Outside of regenerative medicine, this article presents Antibody-Transcription Factor Conjugates (ATFCs) as a new cancer treatment, leveraging iPSC reprogramming concepts in oncology. ATFCs may reprogram tumor cells into non-malignant cell states, offering a substitute for conventional cytotoxic therapies and a reduction in therapy resistance. The review discusses the strategies for optimizing iPSCs and how ATFCs may link regenerative medicine with cancer treatment, promising new directions for personalized medicine and next-generation disease therapy.